Search results for " therapies"

showing 10 items of 112 documents

Intrauterine therapy of goitrous hypothyroidism in a boy with a new compound heterozygous mutation (Y453D and C800R) in the thyroid peroxidase gene. …

2004

We report the results of intrauterine L-thyroxine therapy, and the long-term follow-up in a fetus who presented at 32 weeks' gestation with goitrous hypothyroidism, hyperextension of the neck, and polyhydramnios. Spontaneous delivery was possible and hypothyroidism improved. Molecular analysis revealed a new compound heterozygous mutation (Y453D/C800R) in the TPO gene.

AdultMalePolyhydramniosendocrine systemmedicine.medical_specialtyPolyhydramniosGoiterendocrine system diseasesCompound heterozygosityIodide PeroxidaseInjectionsLoss of heterozygosityHypothyroidismPregnancyInternal medicineCongenital HypothyroidismMedicineHumansThrombopoietinFetusFetal Therapiesbusiness.industryGoiterObstetrics and Gynecologymedicine.diseaseCongenital hypothyroidismFetal DiseasesThyroxineEndocrinologyRetreatmentGestationFemalebusinessFollow-Up StudiesAmerican journal of obstetrics and gynecology
researchProduct

Autosomal Recessive Hypercholesterolemia Long-Term Cardiovascular Outcomes

2017

BACKGROUND Autosomal recessive hypercholesterolemia (ARH) is a rare lipid disorder characterized by premature atherosclerotic cardiovascular disease (ASCVD). There are sparse data for clinical management and cardiovascular outcomes in ARH. OBJECTIVES Evaluation of changes in lipid management, achievement of low-density lipoprotein cholesterol (LDL-C) goals and cardiovascular outcomes in ARH. METHODS Published ARH cases were identified by electronic search. All corresponding authors and physicians known to treat these patients were asked to provide follow-up information, using a standardized protocol. RESULTS We collected data for 52 patients (28 females, 24 males; 31.1 +/- 17.1 years of age…

AdultMaleTime FactorsSettore MED/09 - Medicina InternaAdolescentatherosclerotic cardiovascular disease; autosomal recessive hypercholesterolemia; follow-up; lipid-lowering therapies; retrospective analysisHypercholesterolemiaretrospective analysiatherosclerotic cardiovascular disease; autosomal recessive hypercholesterolemia; follow-up; lipid-lowering therapies; retrospective analysis; Cardiology and Cardiovascular MedicineCohort StudiesYoung Adultautosomal recessive hypercholesterolemialipid-lowering therapiesfollow-upHumansLongitudinal StudiesChildlipid-lowering therapiesAgedRetrospective Studieslipid-lowering therapieatherosclerotic cardiovascular diseaseCholesterol LDLMiddle Agedretrospective analysisTreatment OutcomeCardiovascular DiseasesChild PreschoolFemaleCardiology and Cardiovascular MedicineFollow-Up Studies
researchProduct

Timing of quality of life improvements in psoriatic patients treated with different systemic therapies

2019

Psoriasis impacts the quality of life (QoL) by disrupting overall health and social life. Thus, the use of a QoL evaluation item is crucial in assessing a therapeutic regimen. Also, faster improvements in QoL lead to better patient compliance, but very few studies compare psoriasis traditional and biologic therapies timing. To evaluate how much different systemic therapies improve disease severity and QoL, a retrospective analysis was performed on 56 patients. Subjects were administered different drugs and their vital statistics, psoriasis area severity index (PASI) and PSOdisk were collected at baseline and after 30 days. We found a moderate correlation between PASI and PSOdisk score with …

AdultMalemedicine.medical_specialtyTime FactorsAdolescentAnti-Inflammatory AgentsDermatologySeverity of Illness IndexSocial lifeYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineDisease severityQuality of lifeSurveys and QuestionnairesPsoriasisInternal medicinesystemic therapiesUstekinumabmedicineHumansPsoriasisPatient complianceAgedRetrospective StudiesSkinpsoriasiAged 80 and overTherapeutic regimenbusiness.industryBiologic therapiesAdalimumabGeneral MedicineMiddle Agedmedicine.diseasehumanitiesBiological TherapyTreatment Outcomequality of life030220 oncology & carcinogenesisCyclosporineFemaleUstekinumabDermatologic AgentsbusinessFollow-Up Studiesmedicine.drug
researchProduct

Laboratory Tests in Crohn’s Disease

2015

Laboratory tests are useful for diagnosing Crohn’s disease, assessing disease activity, identifying complications, and monitoring response to therapy. Their role has been considered limited in the past due to lack of specificity. The introduction of biological therapies in inflammatory bowel disease (IBD) has renewed interest in inflammatory markers, especially C-reactive protein (CRP), given their potential to select responders to these treatments. There are several reasons why laboratory markers have been studied in IBD in the past decades: firstly, to gain an objective measurement of disease activity as symptoms are often subjective; secondly, to avoid invasive (endoscopic) procedures wh…

Biological therapiesCrohn's diseasemedicine.medical_specialtyResponse to therapybusiness.industryObjective measurementDiseasemedicine.diseaseIron sucroseInflammatory bowel diseasemedicineIntensive care medicinebusinessIrritable bowel syndromemedicine.drug
researchProduct

A method to enable the investigation of murine bronchial immune cells, their cytokines and mediators.

2007

Innovative therapies for severe lung diseases (such as allergic and chronic asthma, chronic obstructive pulmonary disease or any type of lung cancer) require a detailed understanding of the cellular and immune processes in the lung. This protocol details a method to obtain the immune cells of the bronchi as well as the cytokines and mediators produced by these cells for further investigation. The broncho-alveolar lavage fluid (BALF) is taken by injecting physiological solution through the tracheal tube into the murine airways and carefully regained by winding up the connected syringe. After centrifugation, the resulting BALF supernatant can be stored for detection of cytokines or other medi…

CD4-Positive T-LymphocytesLungbusiness.industryCell Culture TechniquesCentrifugationrespiratory systemmedicine.diseaseGeneral Biochemistry Genetics and Molecular Biologyrespiratory tract diseasesGenetically modified organismMiceImmune systemInnovative Therapiesmedicine.anatomical_structureApoptosisImmunologyMedicineAnimalsCytokinesCentrifugationViability assaybusinessLung cancerBronchoalveolar Lavage FluidLungNature protocols
researchProduct

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological c…

2022

Abstract Background The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages and the emergence of immunotherapy itself. This work aims to study the situation of biomarker testing in Spain. Patients and methods The Thoracic Tumours Registry (TTR) is an observational, prospective, registry-based study that included patients diagnosed with lung cancer and other thoracic tumours, from September 2016 to 2020. This TTR study was sponsored by the Spanish Lung Cancer Group (GECP) Foundation, an independent, scientific, multidisciplinary oncology society that coordinates…

Cancer Research:Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms [DISEASES]Lung NeoplasmsTesting:Biological Factors::Biomarkers [CHEMICALS AND DRUGS]:factores biológicos::biomarcadores [COMPUESTOS QUÍMICOS Y DROGAS]Targeted therapiesPulmons - Càncer:neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares [ENFERMEDADES]Carcinoma Non-Small-Cell LungProto-Oncogene ProteinsGeneticsBiomarkers TumorHumansProspective StudiesCàncerDemographyReceptor Protein-Tyrosine KinasesProtein-Tyrosine KinasesErbB ReceptorsOncologySpainPulmonsMarcadors bioquímicsBiomarkersMetastatic lung cancer
researchProduct

Management of orphan symptoms: ESMO Clinical Practice Guidelines for diagnosis and treatment†

2020

### Highlights There is no clear definition of orphan symptoms. There is a group of symptoms that are seldom evaluated in most symptom assessment tools which can be considered as orphan symptoms.1 These are generally prevalent symptoms that are unaddressed in clinical practice, yet often not reported by the patients or by healthcare professionals.2 Orphan symptoms may be defined as symptoms not regularly assessed in clinical practice, and consequently little studied and not properly treated. No epidemiological or clinical studies generally exist to gauge the prevalence of the symptoms chosen; nevertheless, these symptoms are distressing for patients and their families. Orphan symptoms remai…

Cancer ResearchPediatricsmedicine.medical_specialtydiagnosisoncological therapiesMEDLINElcsh:RC254-282Quality of lifeEpidemiologymedicine1506Restless legs syndromeOriginal Researchtreatmentbusiness.industryEvidence-based medicineorphan symptomsmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensRectal tenesmusclinical practice guidelines; diagnosis; oncological therapies; orphan symptoms; treatmentOncologymedicine.symptombusinessMyoclonusclinical practice guidelinesMuscle crampESMO Open
researchProduct

Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI…

2021

ROMEI, a prospective, observational study in patients with myelofibrosis receiving the oral JAK1/2 inhibitor ruxolitinib in real-world practice, assesses treatment adherence based on the 8-item Morisky Medication Adherence Scale (MMAS-8). Here, we present MMAS-8 results at week 24. Overall, 101 of 188 evaluable patients completed the questionnaire at every visit (full completers). Mean (±standard deviation) total MMAS-8 scores remained stable from week 4 to week 24 in the overall population (7.54 ± 0.77 and 7.67 ± 0.70, respectively) and full completers (7.53 ± 0.79 and 7.67 ± 0.73, respectively). Rates of low (MMAS-8 ˂6) or medium (MMAS-8 ≥ 6 to ˂8) adherence were 25–40% and 26–36%, respec…

Cancer Researchmedicine.medical_specialtyRuxolitinib8-item Morisky Medication Adherence ScalePsychometricsTreatment adherenceruxolitiniboral therapiesMedication AdherenceCohort StudiesTreatment complianceInternal medicineSurveys and QuestionnairesNitrilesmedicineHumansIn patientProspective StudiesProspective cohort studyMyelofibrosistreatment compliance8-item Morisky Medication Adherence Scale oral therapies ruxolitinib treatment compliance Adherencebusiness.industryHematologyJanus Kinase 1Janus Kinase 2Interim analysismedicine.disease8-item Morisky Medication Adherence Scale; Adherence; oral therapies; ruxolitinib; treatment compliancePyrimidinesOncologyAdherencePrimary MyelofibrosisPyrazolesObservational studybusinessmedicine.drugLeukemialymphoma
researchProduct

Assessing Preferences in Patients with Head and Neck Squamous Cell Carcinoma: Phase I and II of Questionnaire Development.

2020

Shared-decision making for head and neck squamous cell carcinoma (HNSCC) is challenged by the difficulty to integrate the patient perception of value within the framework of a multidisciplinary team approach. The aim of this study was to develop a questionnaire to assess the preferences of HNSCC patients with respect to the disease trajectory, expected treatment, and toxicities. In accordance with the standardized EORTC Quality of Life Group&rsquo

Cancer Researchmedicine.medical_specialtyScoring criteriaDiseaselcsh:RC254-282Article03 medical and health sciences0302 clinical medicineQuality of lifehead and neck cancer; multimodal therapies; patient preferences; patient priorities; quality of lifeHealth caremedicineIn patient030212 general & internal medicinemultimodal therapiesneoplasmsbusiness.industryHead and neck cancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensHead and neck squamous-cell carcinoma3. Good healthstomatognathic diseasesPatient perceptionsOncologypatient prioritiesquality of life030220 oncology & carcinogenesisFamily medicinehead and neck cancerbusinesspatient preferences
researchProduct

The use of complementary therapies for chronic pain in Italian hospices.

2013

Scopo: Sebbene ci sia un incremento dell’utilizzo delle Terapie Complemntari (CT) in Europa, ancora è poco noto l’utilizzo di esse negli hospice italiani per il trattamento del dolore cronico. Questa indagine ha lo scopo di descrivere la diffusione delle CT e le loro diverse tipologie impiegate per il trattamento del dolore cronico nel setting assistenziale delle Cure Palliative. Metodi. È stata realizzata una indagine on-line su tutto il campione dei 16 hospices presenti nel territorio della Regione Lazio, utilizzando un questionario adattato e validato per descriverne utilizzo e barriere dell’uso delle CT per il trattamento del dolore cronico oncologico e benigno. Risultati: Il tasso di r…

Complementary TherapiesHospice CareItalyhospices; chronic pain; pain management; humans; hospice care; italy; complementary therapiesPalliative careHospicesHumansPain ManagementNursingComplementary TherapyChronic PainSettore MED/45 - Scienze Infermieristiche Generali Cliniche E Pediatriche
researchProduct